After more than a decade of foundational studies involving protease-activated receptors (PARs), Function Therapeutics, Inc. was founded in 2021 to advance a new class of PAR-targeting anti-inflammatories to the clinic. The original partnership between the labs of Dr. Robert Flaumenhaft (Harvard Medical School) and Dr. Chris Dockendorff (previously at Marquette Univ.) is the foundation for an integrated team of executives, consultants, and collaborators with decades of experience in disease biology, structural biology, medicinal chemistry, and pharmacology.
Chris Dockendorff, PhD
CSO & CEO
Dr. Dockendorff is an organic and medicinal chemist with a passion for the design, synthesis, and study of novel molecules with the potential to improve human health.
Paul Ornstein, Ph.D.
VP of Preclinical Development
Dr. Ornstein has close to 40 years of drug discovery experience as a medicinal chemist at Eli Lilly, followed by faculty positions at Roosevelt University and the Medical College of Wisconsin.
Scientific Advisory Board
William Greenlee, Ph.D.
Dr. Greenlee is an independent medicinal chemistry consultant and former senior director and VP of chemistry at Merck Research Labs & Schering-Plough Research Institute.
Robert Flaumenhaft, M.D., Ph.D.
Dr. Flaumenhaft is Professor of Medicine at Harvard Medical School and presently Chief of the Division of Hemostasis & Thrombosis at Beth Israel Deaconess Medical Center.
Photo Credit: Dan Johnson